September 3, 2014 (Investorideas.com Newswire) Stellar Biotechnologies president and CEO Frank Oakes today presented at the Rodman & Renshaw 2014 Global Investment Conference, where more than 200 biotech, healthcare, technology, natural resources and growth companies are presenting to an audience of more than 1,500 attendees. The conference will be held at the New York Palace Hotel in New York City, September 8-11, 2014.
Oakes took the stage to highlight the Stellar's position and operations a sustainable manufacturer of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets.
This versatile molecule can be combined with a disease-targeting agent to create a novel immunotherapy, or used alone to assess the body's immune response. KLH can only be obtained from a scarce marine source, the Giant Keyhole Limpet, a shelled species native to Southern California and Mexico.
Stellar has developed a patented method for harvesting KLH without harming the Giant Keyhole Limpet. The company's production facilities represent breakthrough achievements such as the first-ever ability to sustain generations of the source in controlled, land-based facilities.
Stellar aims to utilize this method to meet the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production and developing KLH-based active immunotherapies.
NutraNomics (NNRX) Views Recent Product Order as Sign of Present, Future Growth
NutraNomics recently received a $233,000 product order for its line of new weight loss products. The weight loss products are one of NutraNomics' latest innovations formulated by the company's founder Dr. Tracy Gibbs.
The purchase order came from a large Utah-based multi-level marketing company which intends to launch the weight loss product line under its brand sometime this month. NutraNomics retains exclusive rights for manufacturing the product line and hopes to see subsequent orders in the months ahead.
"The quick lead time between the development and the sale of this line of products represents the skill that Dr. Gibbs and the rest of our team has here at NutraNomics," Mike Brousseau, general manager of NutraNomics stated in a news release announcing the purchase order. "We've coordinated the formulation, raw material supply, and production of this line within a three-month time span, showcasing our expertise."
The company anticipates that the recent order will also have a significant, positive impact on strengthening profitability at the company.
"Because our new client has operations in many countries around the world, we expect the new relationship to increase our footprint in the EU and Latin America where we have only a small number of clients," Brousseau stated.
The uniqueness of NutraNomics' products lies in the fact that the supplements have high bioavailability and are made from superior food- and plant-based products blended from the highest quality sources available. The human body is able to recognize the difference between synthetic isolates and real food. When one consumes whole food nutrients, the body engages them as nourishment and can use them to support and maintain a healthy body. NutraNomics' products are also designed to nourish the body at the cellular level, giving the user a renewed energy and vitality.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Published at the Investorideas.com Newswire - Big ideas for Global Investors
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news as well as creates original content as a news source. Original content created by investor ideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and global syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions and advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.